Dr. Miroslav Reljanovic recently spoke to The Telegraph: “The pandemic did two things that forced a rethink of clinical trial structure: it jeopardised the classical way of running trials for non-Covid patients as they were no longer able to go into hospital; meanwhile Covid trials had to speed up urgently. These factors jolted the industry […]
Dr. Miroslav Reljanovic recently spoke to The Telegraph: “The pandemic did two things that forced a rethink of clinical trial structure: it jeopardised the classical way of running trials for non-Covid patients as they were no longer able to go into hospital; meanwhile Covid trials had to speed up urgently. These factors jolted the industry and regulators, …”.
To read more of Dr. Reljanovic’s interview and see the article, click here. To download the full article as PDF, click here.
